Gracell Biotechnologies Inc.
Index- P/E- EPS (ttm)-0.97 Insider Own7.71% Shs Outstand67.30M Perf Week-10.51%
Market Cap207.81M Forward P/E- EPS next Y-0.46 Insider Trans0.00% Shs Float8.65M Perf Month36.36%
Income-63.10M PEG- EPS next Q-0.08 Inst Own47.00% Short Float6.69% Perf Quarter-1.25%
Sales0.37M P/S567.77 EPS this Y-36.70% Inst Trans-4.09% Short Ratio2.67 Perf Half Y-55.45%
Book/sh4.36 P/B0.72 EPS next Y-20.90% ROA-21.70% Target Price19.00 Perf Year-79.08%
Cash/sh4.40 P/C0.72 EPS next 5Y- ROE-30.10% 52W Range1.68 - 16.98 Perf YTD-47.85%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-81.45% Beta-
Dividend %- Quick Ratio14.70 Sales past 5Y- Gross Margin- 52W Low87.50% ATR0.34
Employees202 Current Ratio14.70 Sales Q/Q- Oper. Margin- RSI (14)56.07 Volatility13.47% 13.29%
OptionableNo Debt/Eq0.06 EPS Q/Q27.90% Profit Margin- Rel Volume0.53 Prev Close3.00
ShortableYes LT Debt/Eq0.03 EarningsMay 16 BMO Payout- Avg Volume216.40K Price3.15
Recom1.50 SMA205.40% SMA5024.60% SMA200-53.24% Volume115,161 Change5.00%
Apr-04-22Initiated BTIG Research Buy $18
Feb-03-21Initiated Citigroup Buy $35
Feb-02-21Initiated Wells Fargo Overweight $33
Feb-02-21Initiated Piper Sandler Overweight $40
Feb-02-21Initiated Jefferies Buy $30
May-26-22 05:01PM  
May-19-22 08:30AM  
May-16-22 07:30AM  
May-12-22 10:01AM  
May-04-22 08:30AM  
May-02-22 08:00AM  
Apr-28-22 10:30AM  
Apr-22-22 05:00PM  
Apr-14-22 08:30AM  
Apr-08-22 04:00PM  
Mar-29-22 08:30AM  
Mar-14-22 07:30AM  
Mar-10-22 04:30PM  
Mar-08-22 04:30PM  
Mar-02-22 08:00AM  
Mar-01-22 09:03AM  
Feb-22-22 07:30AM  
Feb-17-22 08:30AM  
Feb-03-22 08:00AM  
Jan-18-22 08:00AM  
Jan-12-22 08:00AM  
Dec-25-21 02:38AM  
Dec-16-21 08:00AM  
Nov-23-21 09:00AM  
Nov-19-21 07:07AM  
Nov-17-21 04:05PM  
Nov-15-21 07:30AM  
Nov-08-21 05:51AM  
Nov-04-21 09:05AM  
Nov-02-21 08:30AM  
Oct-15-21 08:30AM  
Aug-26-21 09:00AM  
Aug-17-21 07:00AM  
Aug-16-21 08:00AM  
Aug-03-21 09:00AM  
Jul-26-21 09:00AM  
Jul-09-21 12:00PM  
Jun-02-21 08:30AM  
May-26-21 09:00AM  
May-25-21 04:01PM  
May-21-21 08:00AM  
May-19-21 05:15PM  
May-17-21 08:00AM  
May-10-21 04:01PM  
Apr-30-21 05:32PM  
Apr-23-21 06:00PM  
Apr-10-21 09:33AM  
Apr-08-21 05:53AM  
Apr-05-21 08:00AM  
Mar-31-21 08:45AM  
Mar-17-21 08:00AM  
Mar-10-21 05:15AM  
Mar-09-21 04:01PM  
Jan-29-21 08:30PM  
Jan-19-21 06:30AM  
Jan-15-21 08:00AM  
Jan-13-21 08:00AM  
Jan-08-21 01:55AM  
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.